123 related articles for article (PubMed ID: 26886154)
1. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.
Quartuccio L; Salvin S; Corazza L; Gandolfo S; Fabris M; De Vita S
Clin Exp Rheumatol; 2016; 34(2):311-4. PubMed ID: 26886154
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
[TBL] [Abstract][Full Text] [Related]
3. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
6. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study.
Seror R; Nocturne G; Lazure T; Hendel-Chavez H; Desmoulins F; Belkhir R; Ravaud P; Benbijja M; Poirier-Colame V; Taoufik Y; Mariette X
Arthritis Res Ther; 2015 Sep; 17(1):241. PubMed ID: 26336930
[TBL] [Abstract][Full Text] [Related]
7. Stratifying primary Sjögren's syndrome: killers in the balance?
Bowman SJ; Fisher BA
Arthritis Res Ther; 2015 Dec; 17():351. PubMed ID: 26639390
[TBL] [Abstract][Full Text] [Related]
8. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome.
Mariette X; Roux S; Zhang J; Bengoufa D; Lavie F; Zhou T; Kimberly R
Ann Rheum Dis; 2003 Feb; 62(2):168-71. PubMed ID: 12525388
[TBL] [Abstract][Full Text] [Related]
9. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
Kadavath S; Bobic S; Efthimiou P
Clin Rheumatol; 2015 Sep; 34(9):1651-2. PubMed ID: 25652332
[TBL] [Abstract][Full Text] [Related]
10. Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjögren's syndrome and rheumatoid arthritis.
Ichikawa Y; Yamada C; Horiki T; Hoshina Y; Uchiyama M; Yamada Y; Toumatu J
Clin Exp Rheumatol; 1998; 16(6):709-15. PubMed ID: 9844764
[TBL] [Abstract][Full Text] [Related]
11. Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome.
Quartuccio L; Mavragani CP; Nezos A; Gandolfo S; Tzioufas AG; De Vita S
Clin Exp Rheumatol; 2017; 35(4):719-720. PubMed ID: 28281461
[No Abstract] [Full Text] [Related]
12. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
13. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
14. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.
Gottenberg JE; Busson M; Cohen-Solal J; Lavie F; Abbed K; Kimberly RP; Sibilia J; Mariette X
Ann Rheum Dis; 2005 Jul; 64(7):1050-5. PubMed ID: 15640273
[TBL] [Abstract][Full Text] [Related]
15. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.
Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S
Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463
[TBL] [Abstract][Full Text] [Related]
16. A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.
Bishton M; Spencer A; Dickinson M; Ritchie D
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):575-8. PubMed ID: 23773449
[TBL] [Abstract][Full Text] [Related]
17. IgA rheumatoid factor in primary Sjogren's syndrome.
Peen E; Mellbye OJ; Haga HJ
Scand J Rheumatol; 2009; 38(1):46-9. PubMed ID: 18942022
[TBL] [Abstract][Full Text] [Related]
18. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.
Jin X; Ding C
Expert Opin Biol Ther; 2013 Feb; 13(2):315-22. PubMed ID: 23268610
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
Zhou Y; Jin L; Kong F; Zhang H; Fang X; Chen Z; Wang G; Li X; Li X
Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
[TBL] [Abstract][Full Text] [Related]
20. Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sjögren's syndrome and widespread pain: evidence for a relatively benign subset.
ter Borg EJ; Kelder JC
Clin Exp Rheumatol; 2014; 32(3):349-53. PubMed ID: 24529195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
